Colin S. Cooper

Colin S. Cooper

Auto-generated profile, based on publicly available information

Colin S. Cooper

Department of Metabolic Health, Norwich Medical School, University of East Anglia, Norwich NR4 7UQ, UK

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2015 in JMIR Medical Informatics
Verified
Journal Article
Open access
JBJoao H Bettencourt-Silva
Joao H Bettencourt-Silva
JCJeremy Clark
Jeremy Clark
CCColin S Cooper
Colin S Cooper
RMRobert D. Mills
Robert D. Mills
VRVictor J Rayward-Smith
Victor J Rayward-Smith
BIBeatriz De la Iglesia
Beatriz De la Iglesia
Clinical informatics, decision support for health professionals, electronic health records, and ehealth infrastructures.

3 September 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
AGAbraham Gihawi
Abraham Gihawi
HWHenry M Wood
Henry M Wood
JCJeremy Clark
Jeremy Clark
JOJustin O’gRady
Justin O’gRady
RERosalind Eeles
Rosalind Eeles
Daniel S BrewerDaniel S Brewer
Daniel S Brewer
Oncomicrobes are estimated to cause 15% of cancers worldwide. When cancer whole-genome sequencing (WGS) data are collected, the microbes present are also sequenced, allowing the investigation of potential etiological and clinical associations. Interrogating the microbial community for 8908 patients encompassing 22 cancer types from the Genomics England WGS dataset revealed that only colorectal tumors exhibited unmistakably distinct microbial communities that can reliably be used to distinguish anatomical site [positive predictive value (PPV) = 0.95]. This pattern was validated in two independent datasets. Potential clinical relevance uncovered by our analyses included accurate detection of alphapapillomaviruses [human papillomavirus (HPV)] in oral cancers, when compared with current clinical standards, and the detection of rare, highly pathogenic viruses such as human T-lymphotropic virus–1. Biomarker investigations demonstrated statistically significant associations ( P < 0.05) between a subset of anaerobic bacteria and survival in certain subtypes of sarcoma. Our results contradict previous claims that each cancer type has a distinct microbiological signature but highlight the potential value of microbial analysis for certain cancers as WGS of tumor samples becomes common in the clinic.

18 January 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
AGAbraham Gihawi
Abraham Gihawi
CCColin S. Cooper
Colin S. Cooper
Daniel S BrewerDaniel S Brewer
Daniel S Brewer
The results published in Poore and Kopylova et al . 2020[1] revealed the possibility of being able to almost perfectly differentiate between types of tumour based on their microbial composition using machine learning models. Whilst we believe that there is the potential for microbial composition to be used in this manner, we have concerns with the manuscript that make us question the certainty of the conclusions drawn. We believe there are issues in the areas of the contribution of contamination, handling of batch effects, false positive classifications and limitations in the machine learning approaches used. This makes it difficult to identify whether the authors have identified true biological signal and how robust these models would be in use as clinical biomarkers. We commend Poore and Kopylova et al . on their approach to open data and reproducibility that has enabled this analysis. We hope that this discourse assists the future development of machine learning models and hypothesis generation in microbiome research.

29 April 2025 in medRxiv
Verified
Preprint
Open access
PDF file
YLYen-Yi Lin
Yen-Yi Lin
HNHamideh Sharifi Noghabi
Hamideh Sharifi Noghabi
SVStanislav Volik
Stanislav Volik
RBRobert Bell
Robert Bell
FSFunda Sar
Funda Sar
CCColin Collins
Colin Collins
Background: Studies of germline variants in prostate cancer (PCa) have largely focused on their connections to cancer predisposition. However, an understanding of how heritable factors contribute to cancer progression and metastasis remain limited. Objective: To identify low frequency to rare germline nonsynonymous variants associated with increased risk for metastatic PCa (mPCa), while providing functional validation. Design: We assembled an extreme phenotype cohort (EPC) of 52 patients diagnosed with predominantly high-grade (Gleason Score (GS) ≥ 8) PCa and > 7 years of follow-up for which localized treatment naïve tumor tissues were available. In half of the cases, the tumor had metastasized to bone, providing an even distribution of bone mPCa and non mPCa cases. Tumor and matched distant benign DNA samples were exome sequenced and analyzed for germline variants with population-wide minor allelic frequencies σ; 2%. Findings were validated using two independent PCa germline cohorts, including a closely matched Australian study biased to aggressive disease (n = 53) and Pan Prostate Cancer Group (PPCG, n = 976). Two mPCa-promoting candidate variants in KDM6B and BRCA2 were engineered into cell lines and functionalized. Results: Germline nonsynonymous rare variants (gnsRVs) identified in 25 DNA Damage Repair (DDR) genes were significantly enriched in the mPCa patients (p=4.57e-06). Conversely, the prevalence of synonymous variants at minor allele frequencies of σ; 2% were similar between the mPCa and non mPCa patients. The predictive power of variants in 53 non-DDR genes was validated in the Australian cohort (p=0.028) and correlated with high-risk PCa in PPCG (p=0.03). KDM6B K973Q showed functional significance despite being annotated as benign in ClinVar, while BRCA2 I1962T showed sensitivity to Olaparib. In total, six EPC variants related to DNA repair or epigenetics were found to alter enzymatic activity. Conclusions: EPCs coupled with low frequency/rare variant analyses may advance understanding of interactions between the germline and tumor in PCa. We identified a series of germline variants that were enriched among mPCa patients. Moreover, we showed that one of these variants confers a metastatic phenotype. Our findings suggest that germline testing at diagnosis may improve treatment stratification in PCa. Patient summary: The presence of specific genetic variants among men with PCa may elevate the risk of mPCa once PCa develops. Knowledge of the variant burden at time of diagnosis may enable accurate stratification of some patients for aggressive therapeutic interventions.